CN100493572C - 一种治疗糖尿病的药物组合物 - Google Patents
一种治疗糖尿病的药物组合物 Download PDFInfo
- Publication number
- CN100493572C CN100493572C CNB2004100202207A CN200410020220A CN100493572C CN 100493572 C CN100493572 C CN 100493572C CN B2004100202207 A CNB2004100202207 A CN B2004100202207A CN 200410020220 A CN200410020220 A CN 200410020220A CN 100493572 C CN100493572 C CN 100493572C
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- fructus
- rhizoma
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 72
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 31
- 229940079593 drug Drugs 0.000 title claims description 26
- 239000000203 mixture Substances 0.000 title claims description 8
- 238000000034 method Methods 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- 239000000284 extract Substances 0.000 claims description 27
- 239000008517 radix Trichosanthis Substances 0.000 claims description 22
- 238000002360 preparation method Methods 0.000 claims description 19
- 238000010992 reflux Methods 0.000 claims description 14
- 238000001291 vacuum drying Methods 0.000 claims description 14
- 230000006837 decompression Effects 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 13
- 238000004064 recycling Methods 0.000 claims description 13
- 241000208340 Araliaceae Species 0.000 claims description 11
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 11
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 11
- 235000008434 ginseng Nutrition 0.000 claims description 11
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 claims description 10
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 10
- 241000207929 Scutellaria Species 0.000 claims description 10
- 241001522129 Pinellia Species 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 241000202726 Bupleurum Species 0.000 abstract 1
- 244000183685 Citrus aurantium Species 0.000 abstract 1
- 235000007716 Citrus aurantium Nutrition 0.000 abstract 1
- 241000219061 Rheum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 241000218989 Trichosanthes Species 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 27
- 210000004369 blood Anatomy 0.000 description 27
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 26
- 235000019441 ethanol Nutrition 0.000 description 24
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 19
- 239000008103 glucose Substances 0.000 description 19
- 239000002775 capsule Substances 0.000 description 18
- 208000024891 symptom Diseases 0.000 description 16
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 15
- 102000004877 Insulin Human genes 0.000 description 14
- 108090001061 Insulin Proteins 0.000 description 14
- 229940125396 insulin Drugs 0.000 description 13
- 230000000694 effects Effects 0.000 description 11
- 239000010135 fructus aurantii immaturus Substances 0.000 description 11
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
- 239000008101 lactose Substances 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 7
- 229960003105 metformin Drugs 0.000 description 7
- 206010022489 Insulin Resistance Diseases 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000012054 meals Nutrition 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 208000005946 Xerostomia Diseases 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 206010013781 dry mouth Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000030159 metabolic disease Diseases 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 208000019901 Anxiety disease Diseases 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 208000002705 Glucose Intolerance Diseases 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 206010023379 Ketoacidosis Diseases 0.000 description 2
- 208000007976 Ketosis Diseases 0.000 description 2
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 238000009207 exercise therapy Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000002218 hypoglycaemic effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 101710095342 Apolipoprotein B Proteins 0.000 description 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 description 1
- 102000018619 Apolipoproteins A Human genes 0.000 description 1
- 108010027004 Apolipoproteins A Proteins 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 208000002230 Diabetic coma Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 102000004195 Isomerases Human genes 0.000 description 1
- 108090000769 Isomerases Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000756042 Polygonatum Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000001610 euglycemic effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000002078 massotherapy Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940127017 oral antidiabetic Drugs 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical compound OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001671 psychotherapy Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
中药TL组 | 二甲双胍组 | |
例数 | 32 | 28 |
男/女 | 17/15 | 14/14 |
年龄 | 54.37±10.54 | 56.07±11.29 |
空腹血糖 | 181.56±57.97 | 184±56.75 |
餐后2小时血糖 | 296.57±89.04 | 303.46±84.46 |
组别 | 例数 | 治疗前 | 治疗后 |
TL组 | 32 | -2.09±0.15 | -1.96±0.14* |
二甲双胍组 | 28 | -2.16±0.17 | -2.03±0.13* |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100202207A CN100493572C (zh) | 2004-07-30 | 2004-07-30 | 一种治疗糖尿病的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100202207A CN100493572C (zh) | 2004-07-30 | 2004-07-30 | 一种治疗糖尿病的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1726929A CN1726929A (zh) | 2006-02-01 |
CN100493572C true CN100493572C (zh) | 2009-06-03 |
Family
ID=35926568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100202207A Active CN100493572C (zh) | 2004-07-30 | 2004-07-30 | 一种治疗糖尿病的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100493572C (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102233077A (zh) * | 2010-04-27 | 2011-11-09 | 天津天士力制药股份有限公司 | 一种药物组合物在制备提高ampk酶活性的药物中的应用 |
CN102233076A (zh) * | 2010-04-27 | 2011-11-09 | 天津天士力制药股份有限公司 | 一种药物组合物在制备通过降低srebp1-c而治疗脂毒性导致的2型糖尿病药物中的应用 |
CN102233074A (zh) * | 2010-04-27 | 2011-11-09 | 天津天士力制药股份有限公司 | 一种药物组合物在制备保护胰岛β细胞功能药物中的应用 |
CN102233078A (zh) * | 2010-04-27 | 2011-11-09 | 天津天士力制药股份有限公司 | 一种药物组合物在制备调节改善胰岛微环境药物中的应用 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5508264B2 (ja) * | 2007-08-02 | 2014-05-28 | テースリー ファーマシューティカル グループ カンパニー リミテッド | 糖尿病治療のための医薬組成物およびその製造方法 |
CN101357181B (zh) * | 2007-08-02 | 2011-09-21 | 天津天士力制药股份有限公司 | 一种含有柴胡的治疗糖尿病的药物及其制备方法 |
CN101357174B (zh) * | 2007-08-02 | 2012-07-04 | 天津天士力制药股份有限公司 | 一种治疗糖尿病的药物组合物 |
CN101357182B (zh) * | 2007-08-02 | 2011-10-05 | 天津天士力制药股份有限公司 | 一种含有乌梅的治疗糖尿病的药物及其制备方法 |
CN101574424B (zh) * | 2008-05-05 | 2013-11-06 | 天士力制药集团股份有限公司 | 一种药物组合物在制备保护胰岛功能药物中的应用 |
TWI419698B (zh) * | 2008-08-08 | 2013-12-21 | Tasly Pharmaceutical Group Co | Pharmaceutical composition for treating diabetes and its preparation method |
CN102233075A (zh) * | 2010-04-27 | 2011-11-09 | 天津天士力制药股份有限公司 | 一种药物组合物在制备通过调节ampk-glut4途径而改善糖代谢紊乱药物中的应用 |
CN102847095A (zh) * | 2011-07-01 | 2013-01-02 | 广州中一药业有限公司 | 一种治疗糖尿病的药物 |
CN104547415A (zh) * | 2014-12-25 | 2015-04-29 | 广东聚智诚科技有限公司 | 一种中药组合物用于制备治疗糖尿病药物中的用途 |
-
2004
- 2004-07-30 CN CNB2004100202207A patent/CN100493572C/zh active Active
Non-Patent Citations (9)
Title |
---|
仝小林应用仲景方治疗糖尿病的经验. 柳红芳.北京中医药大学学报,第24卷第1期. 2001 |
单味中草药降血糖作用的研究. 吕兰薰.陕西中医学院学报,第15卷第3期. 1992 |
单味中草药降血糖作用的研究. 吕兰薰.陕西中医学院学报,第15卷第3期. 1992 * |
小方单方治疗糖尿病近况. 李慧金等.山东中医学院学报,第20卷第5期. 1996 |
小方单方治疗糖尿病近况. 李慧金等.山东中医学院学报,第20卷第5期. 1996 * |
开郁清胃颗粒治疗Ⅱ型糖尿病胃动力障碍52例临床观察. 柳红芳等.中国实验方剂学杂志,第8卷第6期. 2002 |
开郁清胃颗粒治疗Ⅱ型糖尿病胃动力障碍52例临床观察. 柳红芳等.中国实验方剂学杂志,第8卷第6期. 2002 * |
降糖心悟. 仝小林.中国医药学报,第19卷第1期. 2004 |
降糖心悟. 仝小林.中国医药学报,第19卷第1期. 2004 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102233077A (zh) * | 2010-04-27 | 2011-11-09 | 天津天士力制药股份有限公司 | 一种药物组合物在制备提高ampk酶活性的药物中的应用 |
CN102233076A (zh) * | 2010-04-27 | 2011-11-09 | 天津天士力制药股份有限公司 | 一种药物组合物在制备通过降低srebp1-c而治疗脂毒性导致的2型糖尿病药物中的应用 |
CN102233074A (zh) * | 2010-04-27 | 2011-11-09 | 天津天士力制药股份有限公司 | 一种药物组合物在制备保护胰岛β细胞功能药物中的应用 |
CN102233078A (zh) * | 2010-04-27 | 2011-11-09 | 天津天士力制药股份有限公司 | 一种药物组合物在制备调节改善胰岛微环境药物中的应用 |
CN102233076B (zh) * | 2010-04-27 | 2015-08-19 | 天士力制药集团股份有限公司 | 一种药物组合物在制备通过降低srebp1-c而治疗脂毒性导致的2型糖尿病药物中的应用 |
CN102233078B (zh) * | 2010-04-27 | 2015-12-16 | 天士力制药集团股份有限公司 | 一种药物组合物在制备调节改善胰岛微环境药物中的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN1726929A (zh) | 2006-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102028900B (zh) | 一种治疗代谢综合征的中药及其制备方法 | |
CN100493572C (zh) | 一种治疗糖尿病的药物组合物 | |
CN111729064A (zh) | 一种健脾通阳中药组合物及其应用 | |
CN104491342A (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN102462834A (zh) | 一种用于糖尿病患者血糖控制的药物组合物 | |
CN103417846A (zh) | 一种降糖的中药组合物及其制备方法 | |
CN100389804C (zh) | 治疗糖尿病的芪麦苓口服液及其制备方法 | |
CN102631595A (zh) | 治疗2型糖尿病的药物及其制备方法 | |
CN101607031B (zh) | 一种治疗和预防糖尿病的药酒及其制备方法和使用方法 | |
CN106420955A (zh) | 具有辅助降血糖功效的中药组合物及其制备方法和产品 | |
CN103007159B (zh) | 校正胰岛功能的中药制剂 | |
CN101843843A (zh) | 一种治疗糖尿病的中药 | |
CN112336802B (zh) | 一种改善糖尿病糖脂代谢的中药组合物及其应用 | |
CN103230552B (zh) | 一种治疗糖尿病的中药 | |
CN103393938B (zh) | 一种降血糖的中药组合物 | |
CN103211996A (zh) | 一种治疗糖尿病中药的制备方法 | |
CN103520684B (zh) | 一种降血糖的中药复合物 | |
CN102114185B (zh) | 一种治疗2型糖尿病胰岛素抵抗的药物 | |
CN106729304B (zh) | 一种减轻禁食或节食副反应的中药及其制备方法 | |
CN1327879C (zh) | 治疗糖尿病的药物及其制备方法 | |
CN1463734A (zh) | 一种治疗糖尿病的中成药及其制备方法 | |
CN1792374A (zh) | 消渴降糖中药制剂 | |
CN117018105A (zh) | 一种治疗糖耐量减低的中药组合物及其制备方法 | |
CN101199603B (zh) | 一种治疗糖尿病的中药制剂 | |
CN104173857A (zh) | 一种治疗阴阳两虚型2型糖尿病的中药及制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Tianjin Tasly Modern Chinese Medicine Resource Co., Ltd. Assignor: Tianjin Tianshili Pharmaceutical Co., Ltd. Contract record no.: 2011120000158 Denomination of invention: Medicine composition for treating diabetes Granted publication date: 20090603 License type: Exclusive License Open date: 20060201 Record date: 20110824 |
|
C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
CP03 | Change of name, title or address |
Address after: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
CP03 | Change of name, title or address | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220607 Address after: 101-1032, F1, building 3, No. 103, Beiqing Road, Haidian District, Beijing 100081 Patentee after: Beijing zhongyitang Technology Co.,Ltd. Address before: 300410 Tianjin Beichen District Huaihe road and Ting Jiang West Road intersection heaven proud of the park Legal Center Intellectual Property Department Patentee before: TASLY PHARMACEUTICAL GROUP Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
EC01 | Cancellation of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Tianjin Tasly Modern TCM Resources Co.,Ltd. Assignor: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Contract record no.: 2011120000158 Date of cancellation: 20220609 |
|
EM01 | Change of recordation of patent licensing contract |
Change date: 20220608 Contract record no.: 2011120000158 Assignor after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Assignor before: TIANJIN TASLY PHARMACEUTICAL Co.,Ltd. |
|
EM01 | Change of recordation of patent licensing contract |